AOCI at other companies
Other financials
Where this comes from
Reported directly by Monopar Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax.
The official record: Monopar Therapeutics’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →
Ask your AI about Monopar Therapeutics's aoci.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Monopar Therapeutics's AOCI?
- Monopar Therapeutics (MNPR) reported AOCI of $98.52K in Q1 2026.
- How has Monopar Therapeutics's AOCI changed year-over-year?
- Monopar Therapeutics's AOCI increased by 552.3% year-over-year, from -$21.78K to $98.52K.
- What is the long-term trend for Monopar Therapeutics's AOCI?
- Over 5 years (2020 to 2025), Monopar Therapeutics's AOCI has grown at a 75.6% compound annual growth rate (CAGR), from -$7.87K to $131.39K.
- What does AOCI mean?
- Accumulated gains and losses bypassing the income statement — unrealized investment gains/losses, currency translation, pension adjustments, and hedge results.